Search results for "vaccine."

showing 10 items of 789 documents

Differences in Long-COVID Symptoms between Vaccinated and Non-Vaccinated (BNT162b2 Vaccine) Hospitalized COVID-19 Survivors Infected with the Delta V…

2022

This study compared differences in the presence of post-COVID symptoms among vaccinated and non-vaccinated COVID-19 survivors requiring hospitalization due to the Delta (B.1.617.2) variant. This cohort study included hospitalized subjects who had survived SARS-CoV-2 infection (Delta variant) from July to August 2021 in an urban hospital in Madrid, Spain. Individuals were classified as vaccinated if they received full administration (i.e., two doses) of BNT162b2 (“Pfizer-BioNTech”) vaccines. Other vaccines were excluded. Those with just one dose of the BNT162b2 vaccine were considered as non-vaccinated. Patients were scheduled for a telephone interview at a follow-up around six months after …

PharmacologyInfectious DiseasesDrug DiscoveryImmunologyCOVID-19; vaccine; post-COVID; Delta; hospitalizationPharmacology (medical)Vaccines
researchProduct

The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and…

2022

Background: Research shows that in most people, two-dose vaccination helps to shape the humoral response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Further studies are required to learn about the vaccine’s effectiveness after boosting. Methods: We conducted a prospective study among 103 healthcare workers (HCWs) from a regional multi-specialty hospital vaccinated with three doses of the BNT162b2 vaccine. We compared their immunoglobulin G (IgG) titers 14 days after the second dose with those 21 days after the booster. We also compared their anthropometric and body composition parameters with IgG concentrations at the same time points. Results: Twenty-one days aft…

PharmacologyInfectious DiseasesDrug DiscoveryImmunologyPharmacology (medical)IgG antibody; SARS-CoV-2; COVID-19; healthcare workers; humoral response; COVID-19 vaccine; BNT162b2 vaccine; immunization; body composition; boosterVaccines; Volume 10; Issue 10; Pages: 1638
researchProduct

A Vaccine Construction against COVID-19-Associated Mucormycosis Contrived with Immunoinformatics-Based Scavenging of Potential Mucoralean Epitopes

2022

Mucormycosis is a group of infections, caused by multiple fungal species, which affect many human organs and is lethal in immunocompromised patients. During the COVID-19 pandemic, the current wave of mucormycosis is a challenge to medical professionals as its effects are multiplied because of the severity of COVID-19 infection. The variant of concern, Omicron, has been linked to fatal mucormycosis infections in the US and Asia. Consequently, current postdiagnostic treatments of mucormycosis have been rendered unsatisfactory. In this hour of need, a preinfection cure is needed that may prevent lethal infections in immunocompromised individuals. This study proposes a potential vaccine constru…

PharmacologyInfectious DiseasesDrug DiscoveryImmunologymucormycosis; immunoinformatics; vaccine design; vaccine efficacy; population coverage; immune activationvaccine designpopulation coveragePharmacology (medical)vaccine efficacyimmunoinformaticsmucormycosisimmune activationVaccines
researchProduct

The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development.

2022

Antibodies (Abs) are important immune mediators and powerful diagnostic markers in a wide range of infectious diseases. Understanding the humoral immunity or the development of effective antibodies against SARS-CoV-2 is a prerequisite for limiting disease burden in the community and aids in the development of new diagnostic, therapeutic, and vaccination options. Accordingly, the role of antiviral antibodies in the resistance to and diagnosis of SARS-CoV-2 infection was explored. Antibody testing showed the potential in adding important diagnostic value to the routine diagnosis and clinical management of COVID-19. They could also play a critical role in COVID-19 surveillance, allowing for a …

PharmacologyInfectious DiseasesSARS-CoV-2vaccineDrug DiscoveryImmunologyantibodiesCOVID-19serodiagnosticPharmacology (medical)immunotherapytestingVaccines
researchProduct

Ten Actions to Counteract Vaccine Hesitancy Suggested by the Italian Society of Hygiene, Preventive Medicine, and Public Health.

2022

Vaccine hesitancy (VH) is one of the main causes of the widespread decline in vaccination coverage and has become the subject of ongoing debate among public health professionals. The present commentary is a “decalogue” of strategic actions to counteract vaccine hesitancy for public health professionals that comes from the cognitive and formative path put in place by the “Communication in Public Health” working group (WG) of the Italian Society of Hygiene, Preventive Medicine, and Public Health. From the establishment of a national, multidisciplinary WG on VH to the activation of a national monitoring/surveillance system on vaccine hesitancy, several proposals are discussed. The identificati…

PharmacologyInfectious Diseasescollaborating research community of practices counteracting hesitancy health planning tools monitoring systems scientific societies standardized practices vaccine hesitancyDrug DiscoveryImmunologyPharmacology (medical)Vaccines
researchProduct

Rotavirus and the web: analysis of online conversations in Italy during 2020

2021

Rotavirus is the most common cause of severe diarrhea among children worldwide. In 2017, Italy included rotavirus vaccination in its National Immunization Program. The use of social media monitoring, an efficient tool to understand vaccine hesitancy, has increased in recent years; however, only a few examples of such monitoring are available for Italy. Present study analyzed content on online sources, including social media, to identify factors contributing to Italian parents' decisions to vaccinate or not their children against rotavirus. Blogmeter Suite was used to search and analyze conversations related to rotavirus in Italian on online sources during 2020. These data were compared with…

PharmacologyRotavirusmedicine.medical_specialtyVaccination scheduleCommunicationImmunologyVaccinationRotavirus VaccinesCOVID-19Diseasemedicine.disease_causeRotavirus vaccineVaccinationItalyparents rotavirus social media vaccination vaccine hesitancy web listeningFamily medicineRotavirusmedicineImmunology and AllergyHumansActive listeningSocial mediaMisinformationPsychologyChild
researchProduct

Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System

2022

To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, Pfizer-BioNTech) was the first and only authorized vaccine in Italy for selected categories, such as healthcare workers, fragile patients and people aged over 80 years old. To master our knowledge about BNT162b2 adverse reactions (ARs), an active surveillance system based on instant messaging was realized for voluntary participants who had been vaccinated at COVID-19 Vaccination …

PharmacologySARS-CoV-2Immunologyadverse reactionactive surveillance systemadverse reaction; vaccine; coronavirus; SARS-CoV-2; m-RNA; female; young people; active surveillance systemyoung peoplecoronavirufemaleInfectious DiseasesvaccineDrug DiscoveryPharmacology (medical)m-RNAVaccines
researchProduct

Age and Cytokine Gene Variants Modulate the Immunogenicity and Protective Effect of SARS-CoV-2 mRNA-Based Vaccination

2023

The introduction of anti-SARS-CoV-2 vaccines in late 2020 substantially changed the pandemic picture, inducing effective protection in the population. However, individual variability was observed with different levels of cellular response and neutralizing antibodies. We report data on the impact of age, gender, and 16 single nucleotide polymorphisms (SNPs) of cytokine genes on the anti-SARS-CoV-2 IgG titers measured 31 and 105 days after administration of the second dose of BNT162b2 vaccine to 122 healthy subjects from the health care staff of the Palermo University Hospital, Italy. The higher titers at 31 days were measured in the younger subjects and in subjects bearing T-positive genotyp…

PharmacologyTNFA rs1800629anti-SARS-CoV-2 S1/S2 IgGanti-SARS-CoV-2 vaccineSettore MED/07 - Microbiologia E Microbiologia ClinicaImmunologyanti-SARS-CoV-2 vaccine; anti-SARS-CoV-2 S1/S2 IgG; cytokine gene SNPs; <i>IL-1R1 rs2234650</i>; <i>IL-6 rs1800795</i>; <i>IL-4 rs2243250</i>; <i>TNFA rs1800629</i>IL-1R1 rs2234650Infectious DiseasesIL-4 rs2243250Drug DiscoveryIL-6 rs1800795Settore MED/05 - Patologia ClinicaPharmacology (medical)cytokine gene SNPs.
researchProduct

Conjugated vaccines: A new strategy for prevention and protection against pediatric infectious diseases

2002

Pharmacologybusiness.industryPediatric Infectious DiseaseConjugated vaccinesbook.journalMedicinePharmacology (medical)businessbookVirologyCurrent Therapeutic Research
researchProduct

Factors Associated with Anti-SARS-CoV-2 Vaccine Acceptance among Pregnant Women: Data from Outpatient Women Experiencing High-Risk Pregnancy

2023

Pregnant women are at higher risk of severe Coronavirus disease 2019 (COVID-19) complications than non-pregnant women. The initial exclusion of pregnant women from anti-SARS-CoV-2 vaccines clinical trials has caused a lack of conclusive data about safety and efficacy for this vulnerable population. This cross-sectional study aims to define the factors related to vaccination adherence in a sample of women experiencing high-risk pregnancies. The recruited women completed a questionnaire based on the Health Belief Model. Data were analyzed to evaluate the associations between socio-demographic variables and vaccination acceptance through descriptive, univariate and multivariate logistic analys…

PharmacologycommunicationImmunologyvaccine acceptanceInfectious Diseaseseducational levelDrug Discoverygynecologistanti-SARS-CoV-2 vaccinationbarriervaccine hesitancyPharmacology (medical)high-risk pregnant womenCOVIDHealth Belief ModelCOVID Health Belief Model anti-SARS-CoV-2 vaccination barrier communication educational level gynecologist high-risk pregnant women vaccine acceptance vaccine hesitancy
researchProduct